Background Prominent clinical symptoms of COVID-19 include CNS manifestations. However,
it is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the …

Multiorgan and Renal Tropism of SARS-CoV-2 In this autopsy series, the authors found that
SARS-CoV-2 has an organotropism beyond the respiratory tract, including the kidneys, heart…

HBV infection remains a leading cause of death worldwide. IFN-α inhibits viral replication in
vitro and in vivo, and pegylated IFN-α is a commonly administered treatment for individuals …

BACKGROUND & AIMS: Currently approved antivirals rarely cure hepatitis B virus (HBV)
infection. Therefore additional therapeutic strategies interfering with other viral replication steps …

No specific drugs are currently available against hepatitis delta virus (HDV), a defective
virus leading to the most severe form of chronic viral hepatitis in man. The lack of convenient …

Background Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV)
and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing …

[1] Maurice JB, Brodkin E, Arnold F, Navaratnam A, Paine H, Khawar S, et al. Validation of
the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic …

Chronic hepatitis B virus (HBV) infection continues to be a major health burden worldwide; it
can cause various degrees of liver damage and is strongly associated with the development …

Objective The stability of the covalently closed circular DNA (cccDNA) in nuclei of non-dividing
hepatocytes represents a key determinant of HBV persistence. Contrarily, studies with …

Background & Aims Interferon (IFN)-α therapy is not effective for most patients with chronic
hepatitis B virus (HBV) infection for reasons that are not clear. We investigated whether HBV …